Akebia Therapeutics Inc.’s recent filing unveils that its SVP, Chief Legal Officer Hadas Nicole R. unloaded Company’s shares for reported $15140.0 on May 13 ’24. In the deal valued at $1.26 per share,12,016 shares were sold. As a result of this transaction, Hadas Nicole R. now holds 651,243 shares worth roughly $0.92 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Dahan Michel sold 34,840 shares, generating $43,898 in total proceeds. Upon selling the shares at $1.26, the SVP, Chief Operating Officer now owns 672,092 shares.
Before that, Dahan Michel sold 8,661 shares. Akebia Therapeutics Inc. shares valued at $13,684 were divested by the SVP, Chief Operating Officer at a price of $1.58 per share. As a result of the transaction, Dahan Michel now holds 706,932 shares, worth roughly $1.0 million.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late August from “a Neutral” to “a Buy”. Piper Sandler also remained covering AKBA and has increased its forecast on May 31, 2023 with a “an Overweight” recommendation from previously “Neutral” rating. Piper Sandler revised its rating on March 31, 2022. It rated AKBA as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of AKBA
On Tuesday, Akebia Therapeutics Inc. [NASDAQ:AKBA] saw its stock fall -9.03% to $1.41. Over the last five days, the stock has lost -9.03%. Akebia Therapeutics Inc. shares have risen nearly 13.71% since the year began. Nevertheless, the stocks have risen 1.44% over the past one year. While a 52-week high of $2.48 was reached on 03/28/24, a 52-week low of $0.78 was recorded on 06/26/24. SMA at 50 days reached $1.2792, while 200 days put it at $1.3442.
Levels Of Support And Resistance For AKBA Stock
The 24-hour chart illustrates a support level at 1.3533, which if violated will result in even more drops to 1.2967. On the upside, there is a resistance level at 1.5033. A further resistance level may holdings at 1.5967. The Relative Strength Index (RSI) on the 14-day chart is 50.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0126, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.71%. Stochastics %K at 74.05% indicates the stock is a holding.
How much short interest is there in Akebia Therapeutics Inc.?
A steep rise in short interest was recorded in Akebia Therapeutics Inc. stocks on 2024-08-15, growing by 0.28 million shares to a total of 18.95 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-15 was 18.66 million shares. There was a rise of 1.49%, which implies that there is a positive sentiment for the stock.
